Skip to main content

Search

Oral Cavity Oropharyngeal Cancer

Partnership to Intercept Oral Cavity/Oropharyngeal Cancer

The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to intercept oral cavity/oropharyngeal cancer.

Disease Interception Accelerator

Disease Interception Accelerator